Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics.

@article{Aluise2010PreclinicalAD,
  title={Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics.},
  author={Christopher D Aluise and Ren{\~a} A Sowell Robinson and Tina L. Beckett and Michael P Murphy and Jian Cai and William M. Pierce and William R. Markesbery and David Butterfield},
  journal={Neurobiology of disease},
  year={2010},
  volume={39 2},
  pages={221-8}
}
Alzheimer disease (AD) is a neurodegenerative disorder characterized clinically by progressive memory loss and subsequent dementia and neuropathologically by senile plaques, neurofibrillary tangles, and synapse loss. Interestingly, a small percentage of individuals with normal antemortem psychometric scores meet the neuropathological criteria for AD (termed 'preclinical' AD (PCAD)). In this study, inferior parietal lobule (IPL) from PCAD and control subjects was compared for oxidative stress… CONTINUE READING